1. For the Urologist by the Urologist: Essential Concepts in Managing mCRPC

3. Goals

4. Case Study: Newly Diagnosed Low Volume Metastatic Disease

5. CHAARTED: Benefit of Docetaxel

7. Toxicity Grade 3 AE or Greater

8. Treating the Primary Tumor

9. Case Study, Continued

10. Abiraterone COU-AA-302 Trial

11. Enzalutamide PREVAIL Trial

12. Treatment Considerations: Use of Immunotherapy

13. Sipuleucel-T

14. Treatment Considerations: Abiraterone vs Enzalutamide

15. Case Study: mCRPC Progressing Through Second Generation Androgen Axis Inhibitors

16. Further Treatment Considerations

17. Emerging Biomarkers

18. Biomarkers: Mutations of DNA Repair and High Rate of Response to Olaparib

20. Cabazitaxel

21. Conclusions

22. Remaining Questions